CA
NZ
UK
AU
IND
US
In its quarterly filing for the three months ended September 30, 2026, the company reportedNet Incomeof $129.6 million, or $2.25 per diluted share. That compares with $112.4 million, or $1.94 per diluted share, a year earlier, an increase of about 15% in net income …
The company reported third quarter 2026 results on October 29, 2026. Revenue reached a record $73.4 million, compared with $47.6 million in the second quarter of 2026 and $28.0 million in the third quarter of 2025.
Net loss narrowed to $129.3 million, or $0.86 per share, from $173.4 million, or $1.64, a year earlier, an improvement of about 25% on a calculated basis. Per share results also reflect a larger share count of 151.0 million weighted shares against 105.8 million.
Total revenues were $353.2 million, up $232.5 million from $120.7 million, which is about 2.9 times the prior year level on a calculated basis. Net product revenue rose $145.3 million to $253.3 million, which the company attributed to continued commercial expansion driven by patient …
Revenue increased by $38.7 million, or 5%, to $841.5 million. CEO Stephen Kramer said the quarter reflected the strength of a diversified portfolio, including 13% growth in back-up care. Growth was partly offset by lower revenue from full service centers closed over the past …
The company filed itsQuarterly Reportfor the period ended September 30, 2026 on October 29, 2026. Its post-transplant tests and NavDx together made up 86% of revenue in the quarter, against 72% a year earlier, and testing volume was about 75,900, up 51%.
Net sales were $129.3 million, up $1.6 million, or 1.2%, from $127.8 million in the prior year quarter. The company attributed the gain primarily to higher consumerDemandwhile keeping its focus on optimizingAdvertisingspend.
The company attributed the increase primarily to higher home sales volume and average selling price per home. Factory-built housing revenue was $633.7 million, up 18.4%, while financial services revenue was $22.6 million, up 5.8%.
That compares with $9.5 million, or $1.45, in the second quarter of 2026 and $4.7 million, or $0.72, in the third quarter of 2025. On a calculated basis, net income grew about 132% year over year and about 15% sequentially.
After $2.4 million of preferred dividends, the net loss applicable to common stockholders was $3.9 million, or $(0.11) per share, versus $0.05 a year earlier. For the nine months, the common loss narrowed to $(0.12) per share from $(0.25).
Please wait processing your request...